Article Text
PDF
Statistics from Altmetric.com
Question
Question:
Is rivastigmine effective for the treatment of Alzheimer’s disease?
Outcomes:
Cognitive function (measured by psychometric tests); dependency; global impression; functional performance; behavioural disturbance; quality of life; rates of institutionalisation; effect on carer; acceptability of treatment as measured by withdrawal from trials; adverse effects; death.
Methods
Design:
Systematic review with meta-analysis.
Data sources:
The Specialised Register of the Cochrane Dementia and Cognitive Improvement Group (searched from date of inception to December 2005). The Cochrane Library, MEDLINE, PsycINFO, EMBASE, CINAHL and LILACS were searched for records added after December 2005 to March 2008; ongoing and other unpublished trials searched through Novartis, FDA, EMEA, NICE, Google and Copernic websites.
Study selection and analysis:
Randomised, double blind, placebo controlled trials of rivastigmine administered to patients with Alzheimer’s disease or probable Alzheimer’s disease (fulfilling DSM-IV or NINCDS-ADRDA) for more than 2 weeks. Exclusions: non-randomised trials; no allocation concealment. A single reviewer selected studies and assessed the quality of included trials on the basis of allocation concealment. Results from individual studies were combined and odds ratios were used to assess treatment …
Footnotes
-
Source of funding Division of Clinical Geratology, Nuffield Department of Clinical Medicine, University of Oxford, and NHS R&D Executive, UK.
Footnotes
-
Competing interests None.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.